A Hepatic Rebuttal: Clarifying Terlipressin’s Role in Acute-on-Chronic Liver Failure
A recent correspondence in Liver International addresses critical feedback on a pivotal study concerning terlipressin for hepatorenal syndrome (HRS) in patients with early-stage acute-on-chronic liver failure (ACLF). The original research, a focal point in transplant hepatology and advanced liver disease management, evaluated the vasoconstrictor’s efficacy and safety in this high-risk patient population where renal dysfunction significantly impacts mortality. This formal response engages with methodological and interpretive questions raised by the scientific community, reinforcing the study’s conclusions and their importance for clinical decision-making in cirrhosis and portal hypertension complications.
Study Significance: For gastroenterologists and hepatologists managing decompensated cirrhosis, this dialogue underscores the evolving evidence base for terlipressin in specific ACLF phenotypes, directly informing treatment algorithms for hepatorenal syndrome. It highlights the necessity of precise patient stratification in clinical trials for liver failure to optimize therapeutic outcomes and guide future research into pharmacological management of portal hypertension and its sequelae.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
